HUB Innovation Awards

Call for Proposals

Due date for submissions is 5:00 PM EST on July 31st, 2026

SUBMIT APPLICATION PACKAGE HERE

GOAL

The central goal of the HUB Innovation Awards Program is to promote research that explores the development of novel biomaterials-based technologies with high potential for translation. We encourage all researchers studying biomaterials to apply.

The HUB Innovation Awards Program is intended to support research that has strong computational integration, potential to be translated into the clinic, and/or support novel biomaterials-based technologies development. Collaboration among research groups is required to be considered for HUB funding. This year, we are offering two separate submission tracks. Additional information regarding collaborations can be found in Eligibility described below.

Proposed Scope and Objectives

Track 1: Integration of Computational Approaches in Biomaterials Development

Examples of projects considered responsive to Track 1 of the HUB Innovation Awards Program include but are not limited to:

  • Collaborative projects with strong integration of computational approaches in biomaterials development. Proposals should address how the biomaterials research goal is uniquely enabled by an integrative computational approach.

    • Examples of responsive and non-responsive proposals in FAQs

  • New collaborations at the interface of biomaterials and computation

Examples of projects considered non-responsive to Track 1 of the HUB Innovation Awards Program include, but are not limited to:

  • Biomaterials/computational collaborations where computational research is not strongly integrated into proposed work – computation should not be a minor addition to an otherwise complete biomaterials proposal

  • Proposals where the computational component centers on -omics-based analyses – computational components should focus on biomaterials in some way. -Omics-based analyses can still be included as an outcome from a biomaterials study

Track 2: Accelerated Translation of Biomaterials into the Clinic

Examples of projects considered responsive to Track 2 of the HUB Innovation Awards Program include but are not limited to:

  • IND- or IDE-enabling studies (or comparable FDA approval pathway) for late-stage biomaterials technologies

    • Examples include, but are not limited to, toxicology, ISO 10993, PK/PD studies, biocompatibility studies, or materials scale-up

  • Commercialization-enabling studies for late-stage biomaterials-based technologies

Examples of projects considered non-responsive to Track 2 of the HUB Innovation Awards Program include, but are not limited to:

  • Translational proposals that still require proof-of-concept studies or lack a clear target patient population

  • Commercialization proposals where the technology still requires extensive validation

For proposals focused on clinical translation or commercialization of biomaterials technologies, please include the following in your proposal:

  • For Therapeutics/Devices - target patient population and comparison to current standard of care

  • For Assays/Models - clinical use-case and comparison to existing technologies

  • Anticipated regulatory pathway and the key regulatory hurdles Opportunity Funds will help alleviate

  • Status of intellectual property

  • Validated efficacy data in relevant in vivo model and/or NAM

Due date for submissions is 5:00 PM EST on July 31st, 2026

SUBMIT APPLICATION PACKAGE HERE